Autosomal recessive segregation of a truncating mutation of anti-Mullerian type II receptor in a family affected by the persistent Mullerian duct syndrome contrasts with its dominant negative activity in vitro.
[en] Anti-Mullerian hormone belongs to the TGFbeta family whose members exert their effects by signaling through two related serine/threonine kinase receptors. Mutations of the anti-Mullerian hormone type II receptor occur naturally, causing the persistent Mullerian duct syndrome. In a family with two members with persistent Mullerian duct syndrome and one normal sibling, we detected two novel mutations of the anti-Mullerian hormone type II receptor gene. One, transmitted by the mother to her three sons, is a deletion of a single base leading to a stop codon, causing receptor truncation after the transmembrane domain. The other, a missense mutation in the substrate-binding site of the kinase domain, is transmitted by the father to the two sons affected by persistent Mullerian duct syndrome, indicating a recessive autosomal transmission as in other cases of persistent Mullerian duct syndrome. Truncating mutations in receptors of the TGFbeta family exert dominant negative activity, which was seen only when each of the mutant anti-Mullerian hormone receptors was overexpressed in an anti-Mullerian hormone-responsive cell line. We conclude that assessment of dominant activity in vitro, which usually involves overexpression of mutant genes, does not necessarily produce information applicable to clinical conditions, in which mutant and endogenous genes are expressed on a one to one basis.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Messika-Zeitoun, L.
Gouedard, L.
Belville, C.
Dutertre, M.
Lins, Laurence ; Université de Liège - ULiège > Chimie et bio-industries > Centre de Bio. Fond. - Section de Biologie moléc. et numér.
Imbeaud, S.
Hughes, I. A.
Picard, J. Y.
Josso, N.
di Clemente, N.
Language :
English
Title :
Autosomal recessive segregation of a truncating mutation of anti-Mullerian type II receptor in a family affected by the persistent Mullerian duct syndrome contrasts with its dominant negative activity in vitro.
Publication date :
2001
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Jost A. (1953) Problems of fetal endocrinology: The gonadal and hypophyseal hormones. Recent Prog Horm Res 8:379-418.
Di Clemente N., Goxe B., Remy J.J. (1994) Inhibitory effect of AMH upon the expression of aromatase and LH receptors by cultured granulosa cells of rat and porcine immature ovaries. Endocrine 2:553-558.
Rouiller-Fabre V., Carmona S., Abou-Merhi R., Cate R., Habert R., Vigier B. (1998) Effect of anti-Mullerian hormone on Sertoli and Leydig cell functions in fetal and immature rats. Endocrinology 139:1213-1220.
Racine C., Rey R., Forest M.G. (1998) Receptors for anti-Müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc Natl Acad Sci USA 95:594-599.
Teixeira J., Fynn-Thompson E., Payne A., Donahoe P.K. (1999) Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology 140:4732-4738.
Brand T., Schneider M.D. (1995) Inactive type II and type I receptors for TGF-β are dominant inhibitors of TGF-β-dependent transcription. J Biol Chem 270:8274-8284.
Tsuchida K., Vaughan J.M., Wiater E., Gaddy-Kurten D., Vale W.W. (1995) Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Endocrinology 136:5493-5503.
Ishikawa T., Yoshioka H., Ohuchi H., Noji S., Nohno T. (1995) Truncated type II receptor for BMP-4 induces secondary axial structures in Xenopus embryos. Biochem Biophys Res Commun 216:26-33.
Johnson D.W., Berg J.N., Baldwin M.A. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189-195.
Lane K.B., Machado R.D., Pauciulo M.W. (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 26:81-84.
Josso N., Picard J.Y., Imbeaud S., Di Clemente N., Rey R. (1997) Clinical aspects and molecular genetics of the persistent Müllerian duct syndrome. Clin Endocrinol (Oxf) 47:137-144.
Belville C., Josso N., Picard J.Y. (1999) Persistence of Müllerian ducts in males. Am J Med Genet 89:218-224.
Josso N., Picard J.Y., Rey R. (1999) Retained Müllerian ducts: AMH resistance syndrome., Jameson JL, ed. Hormone resistance syndromes. Towota: Humana Press;; 233-244.
Naguib K.K., Teebi A.S., Al-Awadi S.A., El-Khalifa M.Y., Mahfouz E.S. (1989) Familial uterine hernia syndrome: Report of an Arab family with four affected males. Am J Hum Genet 33:180-181.
Imbeaud S., Belville C., Messika-Zeitoun L. (1996) A 27 base-pair deletion of the anti-Müllerian type II receptor gene is the most common cause of the persistent Müllerian duct syndrome. Hum Mol Genet 5:1269-1279.
Imbeaud S., Faure E., Lamarre I. (1995) Insensitivity to anti-Müllerian hormone due to a spontaneous mutation in the human anti-Müllerian hormone receptor. Nat Genet 11:382-388.
Faure E., Gouédard L., Imbeaud S. (1996) Mutant isoforms of the anti-Müllerian hormone type II receptor are not expressed at the cell membrane. J Biol Chem 271:30571-30575.
Di Clemente N., Wilson C.A., Faure E. (1994) Cloning, expression and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol 8:1006-1020.
Dutertre M., Rey R., Porteu A., Josso N., Picard J.Y. (1997) A mouse Sertoli cell line expressing anti-Müllerian hormone and its type II receptor. Mol Cell Endocrinol 136:57-65.
Gouédard L., Chen Y.G., Thevenet L. (2000) Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. J Biol Chem 275:27973-27978.
Ariyaratne H.B.S., MendisHandagama S.M.L.C., Hales D.B., Mason J.I. (2000) Studies on the onset of Leydig precursor cell differentiation in the prepubertal rat testis. Biol Reprod 63:165-171.
Behringer R.R., Cate R.L., Froelick G.J., Palmiter R.D., Brinster R.L. (1990) Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance. Nature 345:167-170.
Hadcock J.R., Malbon C.C. (1988) Down-regulation of β-adrenergic receptors: Agonist-induced reduction in receptor mRNA levels. Proc Natl Acad Sci USA 85:5021-5025.
Allard S., Adin P., Gouédard L. (2000) Molecular mechanisms of hormone-mediated Müllerian duct regression: Involvement of β-catenin. Development 127:3349-3360.
Herkowitz E. (1987) Functional inactivation of genes by dominant negative mutations. Nature 329:219-222.
Krishna V., Chatterjee K., Nagaya T. (1991) Thyroid hormone resistance syndrome: Inhibition of normal receptor function by mutant thyroid hormone receptors. J Clin Invest 87:1977-1984.
Takeda K., Sakurai A., De Groot L.J., Refetoff S. (1992) Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-β gene. J Clin Endocrinol Metab 74:49-55.
Massagué J. (1998) TGF-β signal transduction. Annu Rev Biochem 67:753-791.
Hemmati-Brivanlou A., Melton D.A. (1992) A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos. Nature 359:609-614.
Suzuki A., Thies R.S., Yamaji N. (1994) A truncated bone morphogenetic protein receptor affects dorsal-ventral patterning in the early Xenopus embryo. Proc Natl Acad Sci USA 91:10255-10259.
Wieser R., Attisano L., Wrana J.L., Massagué J. (1993) Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 13:7239-7247.
Knaus P.I., Lindemann D., Decoteau J.F. (1996) Dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 16:3480-3489.
Luo K.X., Lodish H.F. (1997) Positive and negative regulation of type II TGF β receptor signal transduction by autophosphorylation on multiple serine residues. EMBO J 16:1970-1981.
Cárcamo J., Zentella A., Massagué J. (1995) Disruption of transforming growth factor-β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 15:1573-1581.
Yamashita H., Tendijke P., Franzen P., Miyazono K., Heldin C.H. (1994) Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β. J Biol Chem 269:20172-20178.
De Winter J.P., De Vries C.J.M., Van Achterberg T.A.E. (1996) Truncated activin type II receptors inhibit activin bioactivity by the formation of heteromeric complexes with activin type I receptors. Exp Cell Res 224:323-334.
Ten Dike P., Yamashita H., Ichijo H. (1994) Characterization of type-I receptors for transforming growth factor-β and activin. Science 264:101-104.
Kain S.R. (1996) Use of fusion genes in mammalian transfection. Current protocols in molecular biology, 2nd Ed. , Ausubel FM, Brant R, Kingston RE, et al., eds. Cambridge: Wiley & Sons; 963-9611.